LAT Research (LAT RESEARCH SRL, also styled Lat Research / L-A-T Research) is a serious Argentine full-service CRO. It is not a boutique website. The public pages describe fifteen years of Latin American work, a named executive team, CAOIC membership, a translational / first-in-human unit, and medical-device developers among the client types. That profile belongs on a regional RFP.
It still is not the same product as a U.S.-anchored first-in-human / early-feasibility device CRO. Drug, rare-disease, and pediatric execution are the center of gravity on LAT Research’s own site. Device FIH is listed; named device EFS is not. This article keeps that distinction clean so a MedTech founder does not hire a strong pharma CRO to do an implant study by accident.
Facts below are from latresearch.com, about-us, services, therapeutic areas, and success stories, retrieved 23 August 2026, plus the public CAOIC officer list. Company-published counts are labeled as such.
What LAT Research publishes
The about page calls LAT Research “a full-service Contract Research Organization (CRO) with 15 years of experience delivering high-quality clinical research solutions across all Latin American countries,” serving “small and mid-sized biotechs, top 20 pharmaceutical companies, and academic sponsors worldwide.” No logos or sponsor names are attached to that sentence. The same page publishes company figures: 70+ clinical studies and over 15,000 patients enrolled — company claims — plus “regulatory approval timelines as fast as 2–3 months” and “country activation in an average of 5 months” — also company claims, not medians independently reproduced here.
Home-page geography: Argentina, Brasil, México, Chile, Colombia, Uruguay, Bolivia. Services copy also names Peru among LATAM countries for site work. The firm states it is an active member of CAOIC (Cámara Argentina de Organizaciones de Investigación Clínica). Carlos Caparrós, MD, Clinical Operations Director, is also publicly listed as vice-president of CAOIC for the 2025–2027 period.
Leadership on the about page:
- Leylen Colmegna, MD — CEO and Co-Founder. 25+ years in clinical research across sites, pharma, and CROs. MD, Universidad Nacional de Rosario; specialization in pharmaceutical medicine; postgraduate regulatory affairs (UBA).
- Pablo Di Blasi, CPA — Co-Founder and CFO. 30+ years in corporate finance; 20+ in clinical research.
- Carlos Caparrós, MD — Clinical Operations Director. 35 years in the industry; regional ClinOps experience described as including Latin America, Asia Pacific, Australia, New Zealand, and South Africa. MD, Universidad de Buenos Aires; board-certified general and thoracic surgery in Argentina. Also Medical Advisor for the SYNGAP1 Foundation in Argentina.
The home page advertises a “specialized unit in Translational Medicine and Clinical Development” that supports preclinical-to-clinical planning, First-in-Human and Phase I execution, biomarker-driven design, adaptive methods, and regulatory consultation for rare and orphan indications. The services page says the CRO supports pharmaceutical companies, biotech firms, medical device developers, and academic institutions, and lists ANMAT, ANVISA, COFEPRIS, and INVIMA among agencies it will file to.
Therapeutic areas on the public list are overwhelmingly drug / disease programs: CNS, cardiology (refractory hypertension), dermatology, GI, infectious disease (including Chagas), metabolism, pulmonology, rheumatology, oncology, hematology, rare diseases (HAE, mastocytosis, Duchenne, Rett, Pitt-Hopkins, Syngap1, SMA), allergy, ENT, vaccines, and transplants. That list is the honest map of the firm’s published center of gravity.
Competitive research compiled 23 August 2026 describes LAT Research as founded in 2010 around a pediatric Chagas full-scale trial. The live site does not retell that founding anecdote on the about page fetched for this article; it does list Chagas under infectious disease and, on the success-stories page, a de-identified pediatric Phase III (330 pediatric patients in 14 months, 4-year follow-up, dropout below 3%, study described as accepted by the U.S. FDA with a 2020 accelerated-approval outcome). The sponsor of that trial is not named. No named device EFS appears on the pages reviewed.
Where LAT Research is the right tool
Use LAT Research when the protocol is a drug, biologic, vaccine, or rare-disease program that needs Argentine ClinOps depth, CAOIC-fluent ethics/ANMAT navigation, patient-organization relationships, and a personalized full-service model. The translational unit is explicitly built for early-phase medicine. The success-story page is pediatric / regulatory, not implant / ISO 14155.
Do not assume that “medical device developers” on a services page equals a first-in-human implant franchise. Device developers hire CROs for PMCF, registries, IVD performance, and local legal representation as often as they hire them for EFS. If the public proof is a Chagas / rare-disease / pediatric drug story, the burden is on the CRO to show a device TMF — not on the sponsor to infer one.
The product a U.S. device FIH actually buys
A U.S. medtech FIH/EFS implant study is a different product from a LATAM drug Phase I:
- The article is a device, often an implant or delivery system, under ISO 14155, not only ICH E6.
- The customer for the package is FDA (Pre-Sub, IDE, 21 CFR 812.28 eligibility), not only ANMAT.
- Import, sterilization, device accountability, and procedure-room source data dominate start-up.
- n is small (often one or two sites). Staffing must not look like a 70-study pharma engine.
- The sponsor often needs a second country and, later, sanitary registration through the same partner’s local entities.
- The operating language and headquarters the CEO will call are usually English and U.S. Eastern Time.
bioaccess® is built as that product. Co-founded 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark. IMH ASSETS CORP. Miami headquarters (1200 Brickell Ave, Suite 1950 #1034). Regional offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires — so Argentina is already an execution geography, not a subcontract. FIH-only focus since 2010. 50+ pre-qualified sites across 19 countries; 50+ FIH/EFS studies supported; 50+ clients (about page). In Colombia, bioaccess® still runs trials, keeps a local entity and office, manages INVIMA clocks in-country, and has 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. INVIMA is PAHO/WHO Level 4. Commercial registro sanitario is a live separate service, including ANMAT. Pillars: CRO in Colombia, CRO en Colombia.
LAT Research vs bioaccess® — device FIH comparison
| Dimension | LAT Research / LAT RESEARCH SRL | bioaccess® |
|---|---|---|
| Home country | Argentina (Buenos Aires) | United States HQ (Miami); local LATAM entities including Colombia and Argentina office |
| Public age | “15 years” on about page; 2010 founding in competitive maps | Founded 2010; ~16 years of CRO work |
| Primary published mix | Drug / rare disease / pediatric / translational medicine | First-in-human and early-feasibility devices (also biopharma / radiopharma FIH) |
| Device language | Medical-device developers listed as a client type | Device FIH/EFS is the core offer |
| Named device EFS | None on public site | 30+ historical FIH device studies (company-published experience) |
| Named sponsors | None; “top 20 pharmaceutical companies” as a category | Case studies published on bioaccessla.com |
| FIH unit | Translational / Phase I / FIH for high-science (drug-leaning) programs | FIH-only operating model since 2010; FDA Pre-Sub / IDE / 812.28 architecture |
| Company-published scale | 70+ studies, 15,000+ patients (company claim) | 50+ clients; 50+ FIH/EFS supported; 50+ pre-qualified sites (company about page) |
| Association | CAOIC member; Caparrós is CAOIC VP 2025–2027 | Specialist FIH CRO; not positioned as a chamber full-service house |
| After the trial | Full-service clinical + RA filings to ANMAT and peers | Live multi-country sanitary registration / in-country holder |
How to keep LAT Research on the list without confusing the job
If the protocol is a rare-disease drug and Argentina is the lead country, LAT Research is in-category. If the protocol is a first implant for a U.S. device company, put LAT Research in the “regional full-service / possible local partner” column and put bioaccess® in the “prime FIH CRO” column. Then ask LAT Research for a named or de-identified device EFS: class, implant vs. non-implant, n, ISO 14155 monitoring plan, English TMF, and FDA-file use. If that package exists, the two firms can even split work. If it does not, do not learn that after first patient in.
A U.S. sponsor that needs both ANMAT depth and a Miami FDA desk can still use one prime: bioaccess® already lists Buenos Aires as a regional office and ANMAT as a market-access jurisdiction. Request a proposal at contact.
FAQ — LAT Research Argentina and device FIH
Is LAT Research a first-in-human CRO?
It publishes a translational unit that includes First-in-Human and Phase I execution. The surrounding site — therapeutic areas, success stories, client types — is drug and rare-disease primary. Device FIH is claimed, not evidenced with a named EFS on the public site.
Does LAT Research work with medical-device companies?
The services page says yes. That is a client-type sentence. It is not a published implant case series.
Who leads LAT Research?
Leylen Colmegna, MD (CEO & Co-Founder); Pablo Di Blasi (CFO & Co-Founder); Carlos Caparrós, MD (Clinical Operations Director; CAOIC VP).
When should a U.S. MedTech sponsor choose bioaccess® instead?
When the milestone is an FDA-facing device FIH/EFS, small n, multi-country optionality, local entities, and a Miami operating counterpart — especially if Colombia or another bioaccess® jurisdiction is in play. See First-in-Human CRO.
Does bioaccess® still run studies in Colombia?
Yes. Local Colombian entity and office, INVIMA clocks in-country, commercial registro sanitario as a separate live service.
Competitor facts from latresearch.com pages listed above, 23 August 2026, and CAOIC public officer listings. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians. LAT Research’s 2–3 month / 5-month figures are their company claims.